Skip to main content
. Author manuscript; available in PMC: 2019 May 16.
Published in final edited form as: ACS Chem Neurosci. 2018 Feb 13;9(5):1141–1151. doi: 10.1021/acschemneuro.7b00495

Figure 5.

Figure 5

Illustration of the in vitro inverse agonist pharmacology of 5, 6, 8, 10, 11 at the mMC5R. The three-letter amino acid abbreviation for the amino acid in the Phe7 position is provided. Two different pharmacological results were obtained from these studies. For some compounds, a sigmoidal dose-response curve was observed from which an apparent potency and percent cAMP accumulation change from basal can be calculated. Other compounds did not plateau, and for these compounds a percent cAMP accumulation change from basal at 100 μM concentrations is listed.